Med-X inc.

MAKING A DIFFERENCE, NATURALLY.

Spring 2026
Investor Presentation

Disclaimers

Med-X inc.

An Investment in the Company's securities is speculative and the resulting securities will be illiquid. Please be advised that by investing in the offering you could potentially lose your entire investment.

The information in this presentation is being provided so you can familiarize yourself with Med-X (together with its subsidiaries, "Med-X," the "Company," "we," "us," or "our") during this informational meeting. We request that you keep any information we provide at this meeting confidential and that you do not disclose any of the information to any other parties without the Company's prior express written permission. Although the Company believes the information contained herein is accurate in all material respects, the Company does not make any representation or warranty, either express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation.

The information contained in this presentation (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; (d) is for informational purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue or subscribe for any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different.

The presentation includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this presentation regarding, among other things, our strategy, future operations, financial position, anticipated dividends, projected costs, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. The Company expressly disclaims any and all liability relating to or resulting from the use of this presentation. In addition, the information contained in this presentation is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this presentation or other information we provide at this meeting as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein.

Med-X Corporate Overview

Med-X inc.

Med-X is a leading innovator of eco-friendly, biological green scene solutions addressing the international pest control, health and wellness markets.

The company's sales are represented by multiple commercial sales verticals and third-party service providers managed through various domestic and international distribution partners. Retail sales are currently conducted by over-the-counter pharmacy retailers and various e-commerce service providers.

Through our health-conscious, eco-friendly products, we believe that we're creating a safer, greener world for years to come. And because they're made with plants, they cause little to no harm to the environment or to you.

MXRX

**Private –
Nasdaq Symbol Reserved**

Experienced Leadership Team

MATTHEW A. MILLS

CEO, CHAIRMAN

Operations Professional, Oversaw over $200M Revenue Book in Prior Role.

DR. DAVID TOOMEY

CHIEF SCIENCE OFFICER

Clinical Investigator for Big Pharma and Family Physician for more than 24 years.

RONALD J. TCHORZEWSKI

CFO, DIRECTOR

Finance Professional with Over 35 Years of Public Company Experience.

NICK PHILLIPS

CHIEF MEDIA OFFICER

E-Commerce Professional with Significant Experience Scaling Companies.

JENNIFER MILLS

PRESIDENT, DIRECTOR

Project Management and Human Resources Professional.

DR. ALLAN KURTZ

INDEPENDENT DIRECTOR

Internal and Osteopathic Medicine.

Mary Kay Wilson

INDEPENDENT DIRECTOR

Accomplished Executive and Business Owner

MICHAEL KUNTZ

INDEPENDENT DIRECTOR

Financial and Investment Banking Specialist

PROF. FRED DASHIELL, JR.

INDEPENDENT DIRECTOR

Scientist and Mathematician.

The Problem

Med-X inc.

Pests are Dangerous, but so are Pesticides

Health Issues

Pesticide exposure is linked to cancer & chronic diseases, limiting household usage.[1]

Pesticides continue to present collateral damage to the environment. [3]

Vector-Borne Disease

Vector-borne diseases (or diseased transferred by mosquitoes, ticks, etc.) are responsible for over 700,000 deaths per year, growing over 5% annually.[2]

Major Crop Loss

Between 20 and 40% of total global crop production is lost to pest infestations.[4]

Given the inherent health issues, application of chemical pesticides often brings unintended side effects.[1]

Source: 1) National Library of Medicine 2) World Health Organization 3) National Library of Medicine 4) USDA

Biopesticides are Better, Naturally

Med-X inc.

Biopesticides, Derived from Natural Materials, Maintain Key Benefits as Compared to Chemical Pesticides:

Safer For Humans[1]

- Safe for workers to handle
- Healthier for consumers; no dangerous residues
- Able to be used by organic farmers[2]
- Pleasant aroma

Naturally Effective

- Strong Alternative to chemical pesticides
- Environmentally friendly[1]
- Low re-entry time minimizes business interruptions[3]
- Minimal collateral damage risk to pets[1]

Simplified Path to Market

- Faster regulatory approvals[4]
- Sales continuing to grow as Industry professionals adapt
- Simple, routine deployment by pest control experts and consumers

Source: 1) EPA 2) USDA 3) EPA 4) EPA

The Market Opportunity

Med-X inc.

- The Global Biopesticides Market is expected to grow at a compound annual growth rate of 15.1% from $8.6B in 2024 to $40.3B by 2035[1].
- The global pest control industry is expected to grow 5.4% annually from $20.1 billion in 2019 to $44.3 billion in 2034.[2]
- Over 70% of consumers surveyed said they would choose a natural, plant-based pesticide if the effectiveness was the same and the cost was 30% more.[3]
- Governments around the world, particularly in Europe, are banning chemical pesticides, leaving businesses with little to no effective pest control alternatives.[4]

Source: 1. Vantage Market Research. Biopesticides Market by 2030
2. Allied Market Research
3. Survey Monkey
4. The Guardian & Heinrich-Böll-Stiftung

Our Solution: Nature-Cide®

Med-X inc.

NPMA National Pest Management Association Our Mission is Your Protection

PMP Pest Management Professional

PCT Pest Control Technology

Professional & Consumer Product Lines

1. **Full Product Suite:** Consumer and professional variants of core product for every application.
2. **Broadly Applicable:** One product line for all pests in commercial, transportation, Ag, turf and at home.
3. **Proven Effective:** Various laboratory and field tests prove efficacy against insects, various rodents, reptiles and birds.
4. **Naturally Safe:** Pleasant aroma, simple ingredients such as Clove Oil, Cottonseed Oil, Cedar Oil, Cinnamon Oil and other natural ingredients.

A decade in the making, Nature-Cide provides a safe, simple and effective alternative to toxic chemical pesticides.

Nature-Cide Worldwide Target Markets

Med-X inc.


Residential Buildings


Schools


Agriculture


Transportation


Commercial Buildings


Food Service


Parks & Recreation


Hospitality

Med-X Brands: Eco-Friendly Alternatives

Med-X inc.

Nature-Cide®

Nature-Cide products are eco-friendly essential oil blends for indoor and outdoor pest repellent and pest control applications.

thermal-AID®

Thermal-Aid is a line of 100% natural heating & cooling pain and physical therapy products for children and adults.

Malibu Brands are eco-friendly topical essential oil blends designed for pain management for various ailments and a sustainable lifestyle brand.

MALIBU BRANDS

Med-X Product Distribution Model

Med-X inc.

Direct to Consumer (D2C) Sales Channels

Retail & E-Commerce Partners

Walmart
CardinalHealth
Kroger
iHerb
amazon
chewy

Consumer Households

Business to Business (B2B) Sales Channels

Distribution Partners

SiteOne Pest Management
Rentokil
ENSYSTEX™ LEADING INNOVATION IN PEST MANAGEMENT
TARGET SPECIALTY PRODUCTS™
VESERIS

Service Partners

Innovative Products Highly Praised by Consumers



Nature-Cide a Proven Success

Med-X inc.

Sold coast to coast through industry distribution partners and online platforms (i.e. Amazon & Walmart)



Flexible Manufacturing Model

Med-X inc.

In-House Production Capabilities

- Med-X operates a 30,000 sq ft warehouse and assembling facility in California with 5,000 sq ft of office space which gives the company ample room for growth.
- Manufacturing partners deliver ingredients for on-site blending using unique formulations.
- U.S.-based product assembly, packaging, labeling and quality-control is all done in-house.

Global Public Health & WHO Prequalification

Med-X inc.

The Opportunity

Vector-borne diseases from organisms such as Mosquito, account for more than 17% of all infectious diseases, causing more than 700 000 deaths annually.[1] The global vector control market size was valued at USD 23.42 billion in 2025 and is projected to grow from USD 24.96 billion in 2026 to USD 41.61 billion by 2034, exhibiting a CAGR of 6.59% during the forecast period.[2]

Med-X aims to become the first botanical mosquito control product prequalified by the WHO, unlocking access to global public health procurement programs.

Why Botanical Vector Control

Rising insecticide resistance, increasing regulatory pressure on synthetic pesticides, and growing demand for safer solutions are driving the need for botanical alternatives.

Nature-Cide offers plant-based formulations designed for adulticide, larvicide, and barrier treatments — a potential new tool for integrated vector management programs that could support global mosquito control while reducing environmental impact.

Path to WHO Prequalification

WHO PQ requires rigorous validation of:

- Efficacy through laboratory and field studies
- Safety and toxicology data
- Manufacturing quality and consistency

Med-X Progress:

- Independent field studies published in scientific literature
- Ongoing laboratory, wind tunnel, and field testing
- Collaboration with leading mosquito control researchers

Goal: Achieve WHO Prequalification for the first botanical mosquito control technology, enabling global public health deployment.

Key Research Partners



Dr. Jane Bonds, PhD
Leading vector control researcher supporting Med-X's WHO pre-qualification dossier. Led multiple rounds of bioassays, wind tunnel studies, and field trials to validate product performance.

Dr. Kiera Lucas, PhD – Collier County Mosquito Control District
Independent evaluation through laboratory testing, semi-field trials, and operational field studies including ULV adulticide, barrier treatment, and larvicide studies.

Dr. Rui-De Xue, PhD – Anastasia County Mosquito Control District
Conducted the first independent two-year field study evaluating Nature-Cide, published in the Journal of the Florida Mosquito Control Association (2019). Demonstrated strong performance vs. synthetic products across multiple applications.

1) World Health Organization 2) Fortune Buisiness Insights

Building a Platform Company

Med-X inc.

Med-X Plans to Make Complementary, Vertical Acquisitions and Expand its Product Portfolio

Growth Opportunities

We’re expanding global reach through partnerships with Rentokil Initial (32+ countries including the UK and EU), Ensystex (29 countries across Asia, Australia, Africa, and the Middle East), and Anasac (bringing Nature-Cide into South America). Regulatory approvals are underway in **Mexico, the Caribbean, Australia, the Middle East, Southeast Asia, and South America**, while U.S. distribution continues to scale through SiteOne Landscape Supply.

Nature-Cide X2 Plus is gaining traction in public health as a mosquito control solution currently deployed via aerial application in Georgia. We're actively engaging with federal and state agencies for emergency response use, while pursuing WHO-aligned efficacy testing to unlock access to global vector control programs.

New product innovation driving near-term catalysts, including the launch of rodent repellent pouches for professional and retail markets, and advanced larvicide testing for X2 Plus with a focus on balancing efficacy and environmental safety. R&D continues on next-gen natural solutions addressing emerging pest and pathogen threats.

Strategic Acquisitions in opportunities that complement Med-X’s product portfolio and accelerate growth.

Operational Growth by hiring and retaining top talent across R&D, sales, and regulatory functions to execute business strategies efficiently.

Accelerating Brand Awareness by investing in high-impact marketing to boost brand visibility across the health & wellness and pest control sectors.

Product Development Model

Med-X inc.

Two-Pronged Product Development Model Leveraging Internal R&D Know-How with Select Acquisitions of Complementary Products

- **Complementary Product M&A:** Potential to acquire complementary products, apply the Nature-Cide brand and push through the Med-X distribution network.

- **Internal Product Development:** Leveraging years of know-how to apply the Nature-Cide product to new form factors, addressing unique new use cases such as rat control, insecticidal soils, insecticidal paint additives, insecticidal candles and drone applicators for sprayable and granularized products.

INVESTOR CONTACT

Lucas A. Zimmerman
Managing Director – MZ North America
Main: 949-259-4987
Med-X@mzgroup.us

Med-X inc.